Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
Despite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at the advanced or metastatic stage. As a result,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.08.032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128092050227200 |
|---|---|
| author | Sara De Dosso Alexander R. Siebenhüner Thomas Winder Alexander Meisel Ralph Fritsch Christoforos Astaras Petr Szturz Markus Borner |
| author_facet | Sara De Dosso Alexander R. Siebenhüner Thomas Winder Alexander Meisel Ralph Fritsch Christoforos Astaras Petr Szturz Markus Borner |
| author_sort | Sara De Dosso |
| collection | DOAJ |
| description | Despite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at the advanced or metastatic stage. As a result, up to 85% of the cases are unresectable, and systemic chemotherapy is the predominant treatment modality for this patient population. While the current therapeutic strategies for the local disease include surgical resection and adjuvant chemotherapy, FOLFIRINOX and gemcitabine plus nab-paclitaxel regimens are the frontline standard of care in the unresectable locally advanced and metastatic settings. In Switzerland, nanoliposomal irinotecan (nal-IRI) is currently the only regimen approved in the second line following progression on gemcitabine plus nab-paclitaxel, based on the results from the phase III NAPOLI-1 trial. Recently, olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and larotrectinib, a first-in-class tropomyosin receptor kinases (TRK) inhibitor, were added to the treatment armamentarium of patients with a molecularly-defined subset of metastatic adenocarcinoma of the pancreas. This article provides an overview of the current treatment landscape of pancreatic cancer in Switzerland. In addition, we report a case of a long-term survivor with advanced pancreatic adenocarcinoma who achieved a notably good response to nal-IRI plus 5-FU/LV after progression on gemcitabine plus nab-paclitaxel. |
| format | Article |
| id | doaj-art-2633768889ef489dbafd165df4af3e42 |
| institution | OA Journals |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-2633768889ef489dbafd165df4af3e422025-08-20T02:33:30ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062021-06-018210.36000/hbT.OH.2021.08.032Metastatic Pancreatic Cancer: Current Treatment Options for Swiss PatientsSara De DossoAlexander R. SiebenhünerThomas WinderAlexander MeiselRalph FritschChristoforos AstarasPetr SzturzMarkus BornerDespite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at the advanced or metastatic stage. As a result, up to 85% of the cases are unresectable, and systemic chemotherapy is the predominant treatment modality for this patient population. While the current therapeutic strategies for the local disease include surgical resection and adjuvant chemotherapy, FOLFIRINOX and gemcitabine plus nab-paclitaxel regimens are the frontline standard of care in the unresectable locally advanced and metastatic settings. In Switzerland, nanoliposomal irinotecan (nal-IRI) is currently the only regimen approved in the second line following progression on gemcitabine plus nab-paclitaxel, based on the results from the phase III NAPOLI-1 trial. Recently, olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and larotrectinib, a first-in-class tropomyosin receptor kinases (TRK) inhibitor, were added to the treatment armamentarium of patients with a molecularly-defined subset of metastatic adenocarcinoma of the pancreas. This article provides an overview of the current treatment landscape of pancreatic cancer in Switzerland. In addition, we report a case of a long-term survivor with advanced pancreatic adenocarcinoma who achieved a notably good response to nal-IRI plus 5-FU/LV after progression on gemcitabine plus nab-paclitaxel.https://doi.org/10.36000/hbT.OH.2021.08.032 |
| spellingShingle | Sara De Dosso Alexander R. Siebenhüner Thomas Winder Alexander Meisel Ralph Fritsch Christoforos Astaras Petr Szturz Markus Borner Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients healthbook TIMES. Oncology Hematology |
| title | Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients |
| title_full | Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients |
| title_fullStr | Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients |
| title_full_unstemmed | Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients |
| title_short | Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients |
| title_sort | metastatic pancreatic cancer current treatment options for swiss patients |
| url | https://doi.org/10.36000/hbT.OH.2021.08.032 |
| work_keys_str_mv | AT saradedosso metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT alexanderrsiebenhuner metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT thomaswinder metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT alexandermeisel metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT ralphfritsch metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT christoforosastaras metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT petrszturz metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients AT markusborner metastaticpancreaticcancercurrenttreatmentoptionsforswisspatients |